Because the BacVax method is based on genomic and structural vaccinology, any bacteria can be analyzed for targets. Our vaccines will be able to address bacterial infections that currently have no vaccine options available, and we are ready to fill that market.
In addition to human vaccines, BacVax will consider appropriate animal vaccines. Care of both food animals and companion animals also relies heavily on antibiotics, and the resistances that animals develop to the antibiotics can be passed to humans. Our vaccine technologies would target significantly reducing antibiotic expenditure for animals while protecting animal health and reducing antibiotic resistance transfer to humans.